DE Burlo Group Inc. increased its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 65.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,957 shares of the biopharmaceutical company’s stock after acquiring an additional 2,750 shares during the period. DE Burlo Group Inc.’s holdings in Pfizer were worth $233,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Fisher Asset Management LLC grew its position in Pfizer by 3.9% during the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after acquiring an additional 1,275,832 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in Pfizer by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock valued at $1,117,696,000 after buying an additional 2,013,835 shares during the last quarter. Legal & General Group Plc boosted its position in Pfizer by 0.9% in the 2nd quarter. Legal & General Group Plc now owns 31,463,283 shares of the biopharmaceutical company’s stock valued at $1,056,857,000 after buying an additional 292,839 shares during the last quarter. Macquarie Group Ltd. boosted its position in Pfizer by 0.9% in the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after buying an additional 228,405 shares during the last quarter. Finally, Boston Partners boosted its position in Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after buying an additional 1,649,801 shares during the last quarter. Institutional investors and hedge funds own 69.34% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) opened at $35.54 on Wednesday. The company has a market capitalization of $211,840.00, a price-to-earnings ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter last year, the business posted $0.61 EPS. The firm’s revenue was up .9% compared to the same quarter last year. analysts expect that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.60%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio is 78.53%.

A number of research analysts have commented on the company. Deutsche Bank AG set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 10th. Barclays PLC set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and a consensus price target of $38.48.

WARNING: “Pfizer, Inc. (PFE) Shares Bought by DE Burlo Group Inc.” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/22/pfizer-inc-pfe-shares-bought-by-de-burlo-group-inc.html.

In other Pfizer news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares in the company, valued at approximately $4,492,216. The disclosure for this sale can be found here. Insiders sold a total of 366,557 shares of company stock worth $12,532,406 in the last three months. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.